Spero Therapeutics (SPRO) Net Income towards Common Stockholders (QoQ) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122.85% |
| Dec 31, 2025 | 526.87% |
| Sep 30, 2025 | -333.33% |
| Jun 30, 2025 | 87.71% |
| Mar 31, 2025 | 42.40% |
| Dec 31, 2024 | -36.01% |
| Sep 30, 2024 | 0.91% |
| Jun 30, 2024 | -41.15% |
| Mar 31, 2024 | -122.96% |
| Dec 31, 2023 | 1,824.91% |
| Sep 30, 2023 | 73.17% |
| Jun 30, 2023 | 10.22% |
| Mar 31, 2023 | -148.26% |
| Dec 31, 2022 | 339.70% |
| Sep 30, 2022 | 55.84% |
| Jun 30, 2022 | 13.82% |
| Mar 31, 2022 | -9.88% |
| Dec 31, 2021 | -22.25% |
| Sep 30, 2021 | -21.53% |
| Jun 30, 2021 | 4.38% |
| Mar 31, 2021 | -2.98% |
| Dec 31, 2020 | 1.28% |
| Sep 30, 2020 | -3.27% |
| Jun 30, 2020 | 18.57% |
| Mar 31, 2020 | 11.65% |
| Dec 31, 2019 | -45.39% |
| Sep 30, 2019 | -32.34% |
| Jun 30, 2019 | -143.45% |
| Mar 31, 2019 | 48.51% |
| Dec 31, 2018 | -1.30% |
| Sep 30, 2018 | -5.09% |
| Jun 30, 2018 | 6.46% |
| Mar 31, 2018 | 27.94% |
| Dec 31, 2017 | -22.31% |
| Sep 30, 2017 | 0.37% |
| Jun 30, 2017 | -70.00% |
| Mar 31, 2017 | 14.44% |
| Dec 31, 2016 | -12.46% |